Partial Epilepsy

32 registered clinical trials studyying Partial Epilepsy — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Sei NCT05067634	SK Life Science, Inc.	Phase 3
Completed	Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures NCT04903314	SK Life Science, Inc.	Phase 1
Recruiting	Investigating Epilepsy: Screening and Evaluation NCT03478852	National Institute of Neurological Disorders and Stroke (NINDS)	—
Completed	Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures NCT02535091	SK Life Science, Inc.	Phase 3
Completed	Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy NCT02076698	University Hospital, Grenoble	Phase 3
Completed	A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects Wit NCT01866111	SK Life Science, Inc.	Phase 2
Unknown	Multimodal Imaging in Pre-surgical Evaluation of Epilepsy NCT01735032	Hospices Civils de Lyon	—
Terminated	Buspirone Therapy for Localized Epilepsy NCT01496612	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2
Completed	Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures NCT01397968	SK Life Science, Inc.	Phase 2
Completed	Thermographic Examination of Skin Temperatures in Individuals With Focal Onset Epilepsy NCT01373190	Atlantic University	—
Recruiting	Surgery as a Treatment for Medically Intractable Epilepsy NCT01273129	National Institute of Neurological Disorders and Stroke (NINDS)	—
Terminated	PRX-00023 Therapy in Localization-Related Epilepsy NCT01281956	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2
Completed	Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy NCT01190098	The Cleveland Clinic	Phase 4
Completed	Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizu NCT01527513	Bial - Portela C S.A.	Phase 2
Completed	Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy NCT01048255	Vertex Pharmaceuticals Incorporated	Phase 2
Completed	Localizing the Epileptogenic Zone With High Resolution Electroencephalography NCT01090934	Central Hospital, Nancy, France	N/A
Withdrawn	Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy NCT00982787	Oregon Health and Science University	Phase 2
Completed	Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy NCT00908349	Supernus Pharmaceuticals, Inc.	Phase 3
Completed	Improving Lesion Detection in Children With Magnetic Resonance Imaging (MRI)-Negative Partial Epilepsy Using D NCT00894478	The Hospital for Sick Children	—
Completed	Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizur NCT00988429	Bial - Portela C S.A.	Phase 3
Completed	Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbaze NCT00900237	Bial - Portela C S.A.	Phase 1
Completed	Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contrace NCT00898560	Bial - Portela C S.A.	Phase 1
Completed	Language Mapping in Patients With Epilepsy NCT00706160	National Institute of Neurological Disorders and Stroke (NINDS)	—
Completed	A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures NCT00465517	Marinus Pharmaceuticals	Phase 2
Terminated	EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epile NCT00391534	Desitin Arzneimittel GmbH	Phase 3
Terminated	Study Comparing Best Medical Practice With or Without VNS Therapy in Pharmacoresistant Partial Epilepsy Patien NCT00522418	Cyberonics, Inc.	Phase 4
Completed	Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy NCT00957372	Bial - Portela C S.A.	Phase 3
Completed	Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epileps NCT00957047	Bial - Portela C S.A.	Phase 3
Completed	Serotonin Receptors in Seizure Disorders NCT00001932	National Institute of Neurological Disorders and Stroke (NINDS)	—
Completed	Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy NCT00001666	National Institute of Neurological Disorders and Stroke (NINDS)	—
Completed	Metabolic Abnormalities in Children With Epilepsy NCT00001325	National Institute of Neurological Disorders and Stroke (NINDS)	—
Approved For Marketing	Cenobamate Expanded Access Program (EAP) NCT04513860	SK Life Science, Inc.	—